Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease

Annual Review of Nutrition

Volumn 33, Issue , 2013, Pages 231-248

  Scorletti, E ^a   Byrne, C D ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Hepatic lipid metabolism; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Omega 3 fatty acids; Treatment

Indexed keywords

APOLIPOPROTEIN; ARACHIDONIC ACID; CORN OIL; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; LINOLENIC ACID; LIVER X RECEPTOR ALPHA; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOID X RECEPTOR ALPHA; SAFFLOWER OIL; SPHINGOMYELIN PHOSPHODIESTERASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; SUNFLOWER OIL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BLEEDING; CELL TRANSPORT; CHEMICAL STRUCTURE; DIETARY INTAKE; ENTEROHEPATIC CIRCULATION; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; FISH; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPID STORAGE; LIPOGENESIS; LIVER CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN METABOLISM; THROMBOCYTE AGGREGATION; VASOCONSTRICTION;

ADIPOSE TISSUE; DIET, HIGH-FAT; DIETARY CARBOHYDRATES; ENTEROHEPATIC CIRCULATION; FATTY ACIDS, OMEGA-3; FATTY ACIDS, OMEGA-6; FATTY LIVER; HUMANS; LIPID METABOLISM; LIVER;

EID: 84880683621     PISSN: 01999885     EISSN: 15454312     Source Type: Book Series    
DOI: 10.1146/annurev-nutr-071812-161230     Document Type: Article

References (90)

1. -1977. The nomenclature of lipids. Eur. J. Biochem. 79:11-21
2. Araya J, Rodrigo R, Pettinelli P, Araya AV, Poniachik J, Videla LA. 2010. Decreased liver fatty acid Δ-6 and Δ-5 desaturase activity in obese patients. Obesity (Silver Spring) 18:1460-63
3. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. 2009. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J. Hepatol. 51:371-79
4. Bhatia LS, CurzenNP, Calder PC, Byrne CD. 2012. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur. Heart J. 33:1190-200
5. Blasbalg TL, Hibbeln J.R., Ramsden CE, Majchrzak SF, Rawlings RR. 2011. Changes in consumption of omega-3 and omega-6 fatty acids in the United States during the 20th century. Am. J. Clin. Nutr. 93:950-62
6. Boini KM, Zhang C, Xia M, Poklis JL, Li PL. 2010. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J. Pharmacol. Exp. Ther. 334:839-46
7. Botolin D, WangY, Christian B, Jump DB. 2006. Docosahexaenoic acid (22:6,n-3) regulates rat hepatocyte SREBP-1 nuclear abundance by Erk-and 26S proteasome-dependent pathways. J. Lipid Res. 47:181-92
8. Bugianesi E, McCullough AJ, Marchesini G. 2005. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 42:987-1000
9. Burdge GC. 2006. Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot. Essent. Fatty Acids 75:161-68
10. Cai L, Wang Z, Ji A, Meyer JM, van der Westhuyzen DR. 2012. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity. PLoS ONE 7: e36785
11. Calder PC. 2010. Omega-3 fatty acids and inflammatory processes. Nutrients 2:355-74
12. Calder PC, Dangour AD, Diekman C, Eilander A, Koletzko B, et al. 2010. Essential fats for future health. Proceedings of the 9th Unilever Nutrition Symposium, 26-27 May 2010. Eur. J. Clin. Nutr. 64(Suppl. 4):S1-13
13. Calder PC, Yaqoob P. 2009. Understanding omega-3 polyunsaturated fatty acids. Postgrad. Med. 121:148-57
14. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, et al. 2006. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment. Pharmacol. Ther. 23:1143-51
15. Caviglia JM, Gayet C, Ota T, Hernandez-Ono A, Conlon DM, et al. 2011. Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J. Lipid Res. 52:1636-51
16. Chan DC, Watts GF, Mori TA, Barrett PH, Redgrave TG, Beilin LJ. 2003. Randomized controlled trial of the effect of n-3 fatty acid supplementation on themetabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity. Am. J. Clin. Nutr. 77:300-7
17. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. 2011. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 141:1249-53
18. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. 2004. Central role for liver X receptor in insulinmediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc. Natl. Acad. Sci. USA 101:11245-50
19. Chiang JY. 2009. Bile acids: regulation of synthesis. J. Lipid Res. 50:1955-66
20. Claria J, Gonzalez-Periz A, Lopez-Vicario C, Rius B, Titos E. 2011. New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. Front. Immunol. 2:49
21. Clayton PT. 2011. Disorders of bile acid synthesis. J. Inherit. Metab. Dis. 34:593-604
22. Cordain L, Eaton SB, Sebastian A, Mann N, Lindeberg S, et al. 2005. Origins and evolution of the Western diet: health implications for the 21st century. Am. J. Clin. Nutr. 81:341-54
23. D?Alessio A, Al-Lamki RS, Bradley J.R., Pober JS. 2005. Caveolae participate in tumor necrosis factor receptor 1 signaling and internalization in a human endothelial cell line. Am. J. Pathol. 166:1273-82
24. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. 2005. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115:1343-51
25. Elmadfa I, Kornsteiner M. 2009. Fats and fatty acid requirements for adults. Ann. Nutr. Metab. 55:56-75
26. Frangioudakis G, Garrard J, Raddatz K, Nadler JL, Mitchell TW, Schmitz-Peiffer C. 2010. Saturatedand n-6 polyunsaturated-fat diets each induce ceramide accumulation in mouse skeletal muscle: reversal and improvement of glucose tolerance by lipid metabolism inhibitors. Endocrinology 151:4187-96
27. Gatt S, Bierman EL. 1980. Sphingomyelin suppresses the binding and utilization of low density lipoproteins by skin fibroblasts. J. Biol. Chem. 255:3371-76
28. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, et al. 2009. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58: 337-43
29. Holman RT. 1988. George O. Burr and the discovery of essential fatty acids. J. Nutr. 118:535-40
30. Holman RT. 1998. The slow discovery of the importance of ω3 essential fatty acids in human health. J. Nutr. 128:427-33S
31. Iacono A, Raso GM, Canani RB, Calignano A, Meli R. 2011. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms. J. Nutr. Biochem. 22: 699-711
32. Ikegami T, Hyogo H, Honda A, Miyazaki T, Tokushige K, et al. 2012. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. J. Gastroenterol. 47:1257-66
33. Ishii S, Iizuka K, Miller BC, Uyeda K. 2004. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl. Acad. Sci. USA 101:15597-602
34. Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B. 2008. Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem. Phys. Lipids 153:3-13
35. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. 2003. Xylulose 5-phosphate mediates glucoseinduced lipogenesis by xylulose 5-phosphate- activated protein phosphatase in rat liver. Proc. Natl. Acad. Sci. USA 100:5107-12
36. Kalaany NY, Mangelsdorf DJ. 2006. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68:159-91
37. Kamisako T, Tanaka Y, Ikeda T, Yamamoto K, Ogawa H. 2012. Dietary fish oil regulates gene expression of cholesterol and bile acid transporters in mice. Hepatol. Res. 42:321-26
38. Kaur G, Cameron-Smith D, Garg M, Sinclair AJ. 2011. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog. Lipid Res. 50:28-34
39. Kim EH, Bae JS, Hahm KB, Cha JY. 2012. Endogenously synthesized n-3 polyunsaturated fatty acids in fat-1mice ameliorate high-fat diet-induced non-alcoholic fatty liver disease. Biochem. Pharmacol. 84:1359-65
40. Kris-Etherton PM, Harris WS, Appel LJ. 2003. Omega-3 fatty acids and cardiovascular disease: new recommendations from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 23:151-52
41. Le HD, Meisel JA, de Meijer VE, Gura KM, Puder M. 2009. The essentiality of arachidonic acid and docosahexaenoic acid. Prostaglandins Leukot. Essent. Fatty Acids 81:165-70
42. Levene AP, Goldin RD. 2012. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology 61:141-52
43. Levy BD. 2010. Resolvins and protectins: natural pharmacophores for resolution biology. Prostaglandins Leukot. Essent. Fatty Acids 82:327-32
44. Li T, Matozel M, Boehme S, Kong B, Nilsson LM, et al. 2011. Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 53:996-1006
45. Liu P, Anderson RG. 1995. Compartmentalized production of ceramide at the cell surface. J. Biol. Chem. 270:27179-85
46. Lorente-Cebrian S, Bustos M, Marti A, Martinez JA, Moreno-Aliaga MJ. 2009. Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes. Clin. Sci. (Lond.) 117:243-49
47. MaDW, Seo J, Davidson LA, Callaway ES, Fan YY, et al. 2004. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J. 18:1040-42
48. Madonna R, Salerni S, Schiavone D, Glatz JF, Geng YJ, De Caterina R. 2011. Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPARα/-activity in microvascular endothelial cells. Thromb. Haemost. 106:500-10
49. Marsman HA, HegerM, Kloek JJ, Nienhuis SL, van Werven J.R., et al. 2011. Reversal of hepatic steatosis by omega-3 fatty acids measured non-invasively by 1H-magnetic resonance spectroscopy in a rat model. J. Gastroenterol. Hepatol. 26:356-63
50. Merrill AH Jr, Lingrell S, Wang E, Nikolova-Karakashian M, Vales TR, Vance DE. 1995. Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion. J. Biol. Chem. 270:13834-41
51. Meyer BJ. 2011. Are we consuming enough long chain omega-3 polyunsaturated fatty acids for optimal health? Prostaglandins Leukot. Essent. Fatty Acids 85:275-80
52. Meyer BJ, Mann NJ, Lewis JL, Milligan GC, Sinclair AJ, Howe PR. 2003. Dietary intakes and food sources of ω-6 and ω-3 polyunsaturated fatty acids. Lipids 38:391-98
53. Mirmiran P, Hosseinpour-Niazi S, Naderi Z, Bahadoran Z, SadeghiM, Azizi F. 2012. Association between interaction and ratio of ω-3 and ω-6 polyunsaturated fatty acid and the metabolic syndrome in adults. Nutrition 28:856-63
54. Molendi-CosteO, Legry V, Leclercq IA. 2011. Why and howmeet n-3 PUFA dietary recommendations? Gastroenterol. Res. Pract. 2011:364040
55. Moles A, Tarrats N, Morales A, DominguezM, Bataller R, et al. 2010. Acidic sphingomyelinase controls hepatic stellate cell activation and in vivo liver fibrogenesis. Am. J. Pathol. 177:1214-24
56. Musso G, Gambino R, CassaderM. 2009. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 48:1-26
57. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, et al. 2007. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-α-dependent manner. Diabetes 56:1034-41
58. Novak EM, Keller BO, Innis SM. 2012. Metabolic development in the liver and the implications of the n-3 fatty acid supply. Am. J. Physiol. Gastrointest. Liver Physiol. 302:G250-59
59. Olivieri O, Martinelli N, Sandri M, Bassi A, Guarini P, et al. 2005. Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and "insulin- resistant" T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction. Clin. Chem. 51:360-67
60. Opreanu M, Lydic TA, Reid GE, McSorley KM, Esselman WJ, Busik JV. 2010. Inhibition of cytokine signaling in human retinal endothelial cells through downregulation of sphingomyelinases by docosahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 51:3253-63
61. Pachikian BD, Neyrinck AM, Cani PD, Portois L, Deldicque L, et al. 2008. Hepatic steatosis in n-3 fatty acid depleted mice: focus on metabolic alterations related to tissue fatty acid composition. BMC Physiol. 8:21
62. Pagadala M, Kasumov T, McCullough AJ, Zein NN, Kirwan JP. 2012. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol. Metab. 23:365-71
63. Pan M, Maitin V, Parathath S, Andreo U, Lin SX, et al. 2008. Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control. Proc. Natl. Acad. Sci. USA 105:5862-67
64. Pan X, Hussain MM. 2012. Gut triglyceride production. Biochim. Biophys. Acta 1821:727-35
65. Pannu PS, Allahverdian S, Francis GA. 2013. Oxysterol generation and liverXreceptor-dependent reverse cholesterol transport: Not all roads lead to Rome. Mol. Cell. Endocrinol. 368:99-107
66. Papamandjaris AA, MacDougall DE, Jones PJ. 1998. Medium chain fatty acid metabolism and energy expenditure: obesity treatment implications. Life Sci. 62:1203-15
67. Parker HM, Johnson NA, Burdon CA, Cohn JS, O?Connor HT, George J. 2012. Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 56: 944-51
68. Patterson E, Wall R, Fitzgerald GF, Ross RP, Stanton C. 2012. Health implications of high dietary omega-6 polyunsaturated fatty acids. J. Nutr. Metab. 2012:539426
69. Petersen KF, Dufour S, Hariri A, Nelson-Williams C, Foo JN, et al. 2010. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362:1082-89
70. Petrenya N, Dobrodeeva L, Brustad M, Bichkaeva F, Menshikova E, et al. 2011. Fish consumption and socio-economic factors among residents of Arkhangelsk city and the rural Nenets autonomous area. Int. J. Circumpolar Health 70:46-58
71. Phang M, Garg ML, Sinclair AJ. 2009. Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specific-redefining platelet response to fish oils. Prostaglandins Leukot. Essent. Fatty Acids 81:35-40
72. Postic C, Girard J. 2008. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J. Clin. Invest. 118:829-38
73. Puglisi MJ, Hasty AH, Saraswathi V. 2011. The role of adipose tissue in mediating the beneficial effects of dietary fish oil. J. Nutr. Biochem. 22:101-8
74. Schmitz G, Ecker J. 2008. The opposing effects of n-3 and n-6 fatty acids. Prog. Lipid Res. 47:147-55
75. Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. 2011. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin. Nutr. 30:6-19
76. Shearer GC, Savinova OV, Harris WS. 2012. Fish oil-how does it reduce plasma triglycerides? Biochim. Biophys. Acta 1821:843-51
77. Simopoulos AP. 2008. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp. Biol. Med. (Maywood ) 233:674-88
78. Smelt AH. 2010. Triglycerides and gallstone formation. Clin. Chim. Acta 411:1625-31
79. Smit LA, Mozaffarian D, Willett W. 2009. Review of fat and fatty acid requirements and criteria for developing dietary guidelines. Ann. Nutr. Metab. 55:44-55
80. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, et al. 2008. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig. Liver Dis. 40:194-99
81. Sung KC, Jeong WS, Wild SH, Byrne CD. 2012. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35:717-22
82. Takeuchi Y, Yahagi N, Izumida Y, Nishi M, Kubota M, et al. 2010. Polyunsaturated fatty acids selectively suppress sterol regulatory element-binding protein-1 through proteolytic processing and autoloop regulatory circuit. J. Biol. Chem. 285:11681-91
83. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. 2008. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 42:413-18
84. Uyeda K, Yamashita H, Kawaguchi T. 2002. Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage. Biochem. Pharmacol. 63:2075-80
85. Whelan J, Rust C. 2006. Innovative dietary sources of n-3 fatty acids. Annu. Rev. Nutr. 26:75-103
86. Xu H, Barnes GT, Yang Q, Tan G, Yang D, et al. 2003. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112:1821-30
87. Xu J, Christian B, Jump DB. 2006. Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by glucose, n-3 polyunsaturated fatty acids, and peroxisome proliferator-activated receptor-α agonist. J. Biol. Chem. 281:18351-62
88. Zhao A, Yu J, Lew JL, Huang L, Wright SD, Cui J. 2004. Polyunsaturated fatty acids are FXR ligands and differentially regulate expression of FXR targets. DNA Cell Biol. 23:519-26
89. Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. 2008. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J. Gastroenterol. 14:6395-400
90. Zuniga J, Cancino M, Medina F, Varela P, Vargas R, et al. 2011. n-3 PUFA supplementation triggers PPAR-αactivation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemiareperfusion injury. PLoS ONE 6:e28502